A Phase 1/2 interventional study of 350 mg leronlimab and 525 mg leronlimab in Triple Negative Breast Neoplasms, sponsored by CytoDyn, Inc.. Terminated at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by CytoDyn, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.
Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 536th largest by enrollment of the 605 interventional ones that give a count, is one of 54 that started in 2019, is one of 107 in phase 1/2, and was the 309th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 18–75 · Women only
Medical University of South Carolina · Sites in United States
Ages 18+
Stephen Shiao · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 353 · Phase 2 300 · Phase 3 29
First in 2001; this study’s year is marked. 54 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 52 across the 605 interventional studies, 90 across the 38 observational. Of the 338 that completed or were terminated, 179 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
319 of 645 have an industry lead sponsor. The 10 most frequent:
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
CytoDyn, Inc. has 3 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
93 of the studies in Triple Negative Breast Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382286Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | 2027-02 |
| NCT05633654Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | 2027-06 |
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06545331ExelixisStudy of XB010 in Subjects With Solid Tumors | 2026-11-23 |
| NCT02276443M.D. Anderson Cancer CenterMolecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | 2026-11-30 |
Add all 93 to your calendar (.ics) → With an account.
Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC).
Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
Phase Ib
Phase Ib is a dose escalation phase with 3 dose levels (cohorts) of leronlimab (PRO 140) administered in combination with a fixed dose of carboplatin at AUC 5 (area under the curve). This dose finding portion of study will follow a "3+3" designed to determine the maximum tolerated dose (MTD) of leronlimab (PRO 140) administered as subcutaneous (SC) injection in subjects with histologically confirmed mTNBC that express CCR5.
Phase II
Phase II is a single arm study with 30 patients in order to test the hypothesis that the combination of carboplatin AUC 5 intravenously and MTD of leronlimab (PRO 140) SC will increase Progression Free Survival (PFS) in patients with CCR5 + mTNBC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Demonstrate CCR5 + by IHC (>10% membranous staining completed at the reference laboratory of Dr. Hallgeir Rui at Medical College of Wisconsin).
Note: This test will be done as part of the pre-screening period. It will be performed in archival tissue. If is not available then, fresh biopsy will be done;
Phase 1 study section:
Subjects must have disease recurrence and progression after ≤ 2 in metastatic setting but untreated with carboplatin;
Phase 2 study section:
Subjects must be naive to chemotherapy or untreated with carboplatin in metastatic setting (first-line) OR excluding carboplatin chemotherapy, subjects must have failed first-line combination of chemotherapy and a in metastatic setting;
Patients must have adequate organ and bone marrow function within 28 days prior to registration, as defined below:
Females of (FOCBP) and males must agree to use two medically accepted methods of with hormonal or barrier method of birth control, or abstinence, prior to study entry, for the duration of study participation and for 60 days after the last dose of study drug (Refer to Appendix 1). Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Note: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
Drug: 350 mg leronlimab · Drug: AUC 5 Carboplatin
Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
Drug: 525 mg leronlimab · Drug: AUC 5 Carboplatin
Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
Drug: 700 mg leronlimab · Drug: AUC 5 Carboplatin
MTD PRO 140 SC + AUC 5 Carboplatin
Drug: AUC 5 Carboplatin · Drug: Maximum Tolerated Dose (MTD) of leronlimab
leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Also known as: PRO 140
leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Also known as: PRO 140
leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Also known as: PRO 140
Carboplatin is an anticancer drug chemotherapy drug.
Also known as: Paraplatin
The decision on the MTD will be made following the results obtained from Phase I studies
Also known as: PRO 140
Phase I: Maximum Tolerated Dose (MTD) of Leronlimab (PRO 140) When Combined With Carboplatin AUC5
The MTD is defined as 1 dose level (cohort) below the dose in which dose limiting toxicities (DLTs) were observed in \>= 33% of the participants.
Time frame: From treatment cycle 1 day 1 (C1D1) until MTD reached (each cycle being 3 weeks), up to 26 weeks
Phase II: Progression Free Survival (PFS) Defined as Time in Months From the Date of First Study Treatment to the Date of Disease Progression or Death From Any Cause, Whichever Comes First.
All patients who received at least one dose of leronlimab (PRO 140) and carboplatin combination was intended to be included in the primary analyses of PFS. The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria was planned to be used for objective tumor response assessment.
Time frame: Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment
Phase I: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE) Collected From the Time of First Treatment Until Study Termination to Evaluate Safety of Leronlimab (PRO 140) and Carboplatin in Subjects With CCR5+ mTNBC.
For Phase I: Adverse events followed National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This will be the Number of Participants with Any Adverse Events (AE) or Serious Adverse Events (SAE) collected from the time of first treatment until study termination to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ metastatic triple negative breast cancer.
Time frame: From Cycle 1, Day 1 (each treatment cycle is 3 weeks) until last dose of study drug, up to 26 weeks
Phase II: Progression Free Survival (PFS) According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1)
Phase II: Progression Free Survival (PFS) according to RECIST v1.1 in participants with Detectable Programmed Death-Ligand 1 (PD-L1) Trial was terminated prematurely and no efficacy data was collected from the Phase II portion.
Time frame: Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment
Phase II: Overall Response Rate (ORR, Defined as Complete Response (CR) + Partial Response (PR)), and Clinical Benefit Rate (CBR, Defined as CR + PR + Stable Disease (SD)) in Subjects With CCR5+ mTNBC Treated With Leronlimab (PRO 140) and Carboplatin.
Phase II: Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)), and clinical benefit rate (CBR, defined as CR + PR + Stable Disease (SD)) in subjects with CCR5+ mTNBC treated with The trial was terminated early, efficacy data is not available
Time frame: Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment
Phase II: Time to New Metastases (TTNM)
Trial was terminated prematurely and no efficacy data was collected.
Time frame: Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment
Phase II: The Change From Baseline in Circulating Tumor Cells (CTC) Level in the Peripheral Blood.
Phase II: The change from baseline in circulating tumor cells (CTC) level in the peripheral blood. No efficacy data was available due to early termination of the trial.
Time frame: Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.
Phase II: Overall Survival Defined as Time in Months From the Date of First Study Treatment to the Date of Death;
Phase II: Overall survival defined as time in months from the date of first study treatment to the date of death; No efficacy data is available due to early termination of the trial.
Time frame: Planned from Day 1 to death from any cause, assessing up to 2 years after completion of treatment.
Phase II: Number, Frequency, and Severity of AEs Collected From the Time of First Treatment Until 12 Weeks After Study Treatment Completion to Evaluate Safety of Leronlimab (PRO 140) and Carboplatin in Subjects With CCR5+ mTNBC.
Phase II: Number, frequency, and severity of AEs collected from the time of first treatment until 12 weeks after study treatment completion to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ mTNBC. No safety data was available from the Phase II portion of the trial due to early termination of the study.
Time frame: Planned from Cycle 1, Day 1 (each treatment cycle is 21 days) to 12 weeks after the last dose of study drug)
Measure Immune Biomarkers (PD-L1) in CTCs, Metastatic Tissue and Immune Cells Such as Cancer Associated Macrophage-like Cells (CAMLs) and Correlate With Therapeutic Benefit (PFS)
Measure immune biomarkers (PD-L1) in CTCs, metastatic tissue and immune cells such as CAMLs and correlate with therapeutic benefit (PFS) No subjects were included in this outcome measure due to early termination of the trial.
Time frame: Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.
Correlation Between CCR5 Expression (CTCs, CAMLs) and PD- L1 Expression.
No subjects were included in this outcome measure due to early termination of the trial.
Time frame: Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.
| Milestone | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment |
|---|---|---|---|---|
| Started | 3 | 4 | 3 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 3 | 4 | 3 | 0 |
| Withdrew: Early termination of study | 3 | 4 | 3 | 0 |
The MTD is defined as 1 dose level (cohort) below the dose in which dose limiting toxicities (DLTs) were observed in \>= 33% of the participants.
| mg | Phase 1b: Including 3 Dose Levels (Cohort A, Cohort B, and Cohort C) |
|---|---|
| Phase I: Maximum Tolerated Dose (MTD) of Leronlimab (PRO 140) When Combined With Carboplatin AUC5 | 700 |
All patients who received at least one dose of leronlimab (PRO 140) and carboplatin combination was intended to be included in the primary analyses of PFS. The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria was planned to be used for objective tumor response assessment.
No measurements were reported for this outcome.
For Phase I: Adverse events followed National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This will be the Number of Participants with Any Adverse Events (AE) or Serious Adverse Events (SAE) collected from the time of first treatment until study termination to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ metastatic triple negative breast cancer.
| Participants | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin |
|---|---|---|---|
| Participants with any AEs | 3 | 4 | 2 |
| Participants with any SAEs | 1 | 1 | 0 |
Phase II: Progression Free Survival (PFS) according to RECIST v1.1 in participants with Detectable Programmed Death-Ligand 1 (PD-L1) Trial was terminated prematurely and no efficacy data was collected from the Phase II portion.
No measurements were reported for this outcome.
Phase II: Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)), and clinical benefit rate (CBR, defined as CR + PR + Stable Disease (SD)) in subjects with CCR5+ mTNBC treated with The trial was terminated early, efficacy data is not available
No measurements were reported for this outcome.
Trial was terminated prematurely and no efficacy data was collected.
No measurements were reported for this outcome.
Phase II: The change from baseline in circulating tumor cells (CTC) level in the peripheral blood. No efficacy data was available due to early termination of the trial.
No measurements were reported for this outcome.
Phase II: Overall survival defined as time in months from the date of first study treatment to the date of death; No efficacy data is available due to early termination of the trial.
No measurements were reported for this outcome.
Phase II: Number, frequency, and severity of AEs collected from the time of first treatment until 12 weeks after study treatment completion to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ mTNBC. No safety data was available from the Phase II portion of the trial due to early termination of the study.
No measurements were reported for this outcome.
Measure immune biomarkers (PD-L1) in CTCs, metastatic tissue and immune cells such as CAMLs and correlate with therapeutic benefit (PFS) No subjects were included in this outcome measure due to early termination of the trial.
Results for this outcome have not been posted.
No subjects were included in this outcome measure due to early termination of the trial.
Results for this outcome have not been posted.
Collected over Adverse events were reported from the time of first treatment until the early termination of the study to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ mTNBC (up to approximately 30 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase II- MTD to be Established for the Combination Treatment | — | — | — |
| Event | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment |
|---|---|---|---|---|
| SepsisInfections and infestations | 1/3 | 0/4 | 0/3 | — |
| HeadacheNervous system disorders | 0/3 | 1/4 | 0/3 | — |
| Event | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment |
|---|---|---|---|---|
| FatigueGeneral disorders | 1/3 | 4/4 | 1/3 | — |
| HeadacheNervous system disorders | 1/3 | 2/4 | 1/3 | — |
| HypertensionVascular disorders | 0/3 | 2/4 | 0/3 | — |
| Back PainMusculoskeletal and connective tissue disorders | 1/3 | 0/4 | 0/3 | — |
| ErythemaSkin and subcutaneous tissue disorders | 1/3 | 0/4 | 0/3 | — |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/4 | 1/3 | — |
| Platelet Count DecreasedInvestigations | 1/3 | 0/4 | 1/3 | — |
| NauseaGastrointestinal disorders | 1/3 | 1/4 | 1/3 | — |
| Neutrophil Count DecreasedInvestigations | 1/3 | 1/4 | 1/3 | — |
| ConstipationGastrointestinal disorders | 1/3 | 1/4 | 1/3 | — |
All patients who received at least one dose of leronlimab (PRO 140) were included in the baseline analysis population. Study was early terminated and no participants were enrolled to the Phase II arm of the trial.
| Age, Categorical(Participants) | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | — | 0 |
| Between 18 and 65 years | 3 | 3 | 2 | — | 8 |
| >=65 years | 0 | 1 | 1 | — | 2 |
| Age, Continuous(years) | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment | Total |
|---|---|---|---|---|---|
| Mean | 41.67 ± 7.76 | 55.75 ± 11.32 | 61.67 ± 8.73 | — | 53.30 ± 12.50 |
| Sex: Female, Male(Participants) | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 3 | — | 10 |
| Male | 0 | 0 | 0 | — | 0 |
| Ethnicity (NIH/OMB)(Participants) | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | — | 0 |
| Not Hispanic or Latino | 2 | 4 | 3 | — | 9 |
| Unknown or Not Reported | 1 | 0 | 0 | — | 1 |
| Race (NIH/OMB)(Participants) | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | — | 0 |
| Asian | 1 | 1 | 0 | — | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | — | 0 |
| Black or African American | 0 | 0 | 0 | — | 0 |
| White | 1 | 3 | 3 | — | 7 |
| More than one race | 0 | 0 | 0 | — | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | — | 1 |
| Region of Enrollment(participants) | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment | Total |
|---|---|---|---|---|---|
| United States | 3 | 4 | 3 | — | 10 |
| Height(cm) | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment | Total |
|---|---|---|---|---|---|
| Mean | 160.05 ± 2.55 | 162.85 ± 6.23 | 164.30 ± 3.30 | — | 162.51 ± 5.11 |
| Weight(kg) | Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin | Phase II- MTD to be Established for the Combination Treatment | Total |
|---|---|---|---|---|---|
| Mean | 85.73 ± 32.08 | 66.50 ± 3.54 | 82.90 ± 11.40 | — | 76.60 ± 21.44 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Jul 2022, 38 months.
Results were first posted in Sep 2025, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab
Triple Negative Breast Neoplasms →